ResMed Inc. (RMD)
ResMed (RMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed Inc. (RMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
ResMed Inc. (RMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is This the Right Time to Add Resmed Stock to Your Portfolio?
RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could weigh on future performance.
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort
Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
Should You Continue to Hold RMD Stock in Your Portfolio?
Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.
IDEXX Laboratories Vs ResMed: Which Stock Could Rally?
IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.
ResMed: Safe Bet For A Recession Environment
ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.
Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand
RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.
